Oculus Innovative Sciences, Inc. Reports Revenues Of $2.9 Million And Net Income Of $7.5 Million For Fourth Quarter Of Fiscal 2014 Primarily Due To Accounting Treatment Of Ruthigen IPO Transaction

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PETALUMA, Calif., June 12, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced financial results for the fourth quarter of fiscal year 2014, ended March 31, 2014. Net income increased $9.9 million to $7.5 million, mostly due to the accounting treatment of Oculus’ investment in Ruthigen. Total revenues were $2.9 million for the fourth quarter, down $421,000, as compared to $3.3 million for the same period in the prior year. Product revenue, including product licensing fees received, was down $509,000, or 16%, with decreases in United States, Mexico and China, which was partially offset by revenue growth in Europe, Middle East, India and Singapore.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC